Summary & Overview
HCPCS S3853: Genetic Testing for Myotonic Muscular Dystrophy
HCPCS Level II code S3853 denotes genetic testing for myotonic muscular dystrophy, a targeted molecular diagnostic service used to confirm or clarify a suspected hereditary neuromuscular condition. Nationally, access to and coverage of genetic testing for myotonic dystrophy affect diagnostic pathways, family planning decisions, and specialist care coordination for patients with progressive muscle weakness and systemic involvement.
Key payers covered in this overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise account of what the code represents, typical sites of service, and the clinical context for ordering the test. The publication outlines expected benchmarks, common billing practices, and recent policy trends relevant to molecular diagnostic services at a national level.
The analysis provides guidance on billing classification, payer coverage considerations, and where this service fits within neuromuscular diagnostic workflows. For payers and provider billing teams, the summary clarifies the role of S3853 in claims submission and highlights areas where additional documentation or medical necessity rationale is commonly required. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code S3853 represents genetic testing for myotonic muscular dystrophy. This service involves laboratory-based molecular diagnostic testing to detect genetic variants associated with myotonic dystrophy, a hereditary neuromuscular disorder that affects muscle function and can have multisystem manifestations.
Service type: Genetic diagnostic testing — laboratory-based molecular analysis.
Typical site of service: Reference or clinical diagnostic laboratory; specimen collection may occur in outpatient clinics, physician offices, or ambulatory collection centers.
Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.
Clinical & Coding Specifications
Clinical Context
A 28-year-old patient presents to a neuromuscular clinic with progressive distal muscle weakness, grip myotonia, cataracts, and a family history of myotonic dystrophy. The neurologist documents symptom onset, family history, and abnormal neuromuscular exam findings and orders S3853 (genetic testing for myotonic muscular dystrophy) to confirm a diagnosis and determine CTG repeat expansion size for prognostic counseling. A blood draw is performed in the outpatient laboratory; DNA is extracted and analyzed using repeat-primed PCR and/or Southern blot as indicated by repeat length. Results are reported to the ordering provider with genetic counseling recommended for the patient and at-risk relatives. Typical site of service is an outpatient clinic, ambulatory laboratory, or hospital outpatient department.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier / standard service | Use for routine genetic testing claims with no modifier required |
22 | Increased procedural services | Use when testing required significantly greater resources or complexity than typical (rare for standard assays) |